`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`______________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`______________
`
`FRESENIUS KABI USA, LLC,
`Petitioner,
`
`v.
`
`NOVO NORDISK A/S,
`Patent Owner.
`______________
`
`Case IPR2022-00657
`Patent 8,114,833
`______________
`
`
`PATENT OWNER’S UPDATED EXHIBIT LIST
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`IPR2022-00657
`Patent 8,114,833
`
`Exhibit No.
`2001
`
`2002
`
`2003
`
`2004
`
`2005
`2006
`
`2007
`
`2008
`
`EXHIBIT LIST
`
`
`Description
`Declaration of Ryan P. Johnson in Support of Patent Owner’s
`Motion for Admission Pro Hac Vice of Ryan P. Johnson.
`Declaration of Laura T. Moran in Support of Patent Owner’s
`Motion for Admission Pro Hac Vice of Laura T. Moran.
`March 13, 2012 Submission From Patent Owner to FDA
`Requesting Approved Drug Products with Therapeutic
`Equivalence Evaluations (the “Orange Book”) Listing of the ’833
`patent
`Excerpt from the 2013 Annual Edition of the Approved Drug
`Products with Therapeutic Equivalence Evaluations (the “Orange
`Book”), Victoza® Listing
`European Patent 1,687,019 B1
`Fresenius Kabi Deutschland GmbH Notice of Opposition Against
`European Patent 1,687,019 B1
`Confidential Settlement Agreement (Business Confidential
`Information)
`Confidential Settlement Agreement (Business Confidential
`Information)
`
`
`
`
`
`
`
`
`1
`
`
`
`CERTIFICATE OF SERVICE
`
`IPR2022-00657
`Patent 8,114,833
`
`Pursuant to 37 C.F.R. §§ 42.6 and 42.105, I hereby certify that the foregoing
`
`document was served on September 7, 2022, by filing this document through the
`
`Patent Trial and Appeal Board End to End System, as well as delivering a copy via
`
`electronic mail upon the following attorneys of record for the Petitioner:
`
`Linnea Cipriano (Reg. No. 67,729)
`GOODWIN PROCTER LLP
`The New York Times Building
`620 Eighth Avenue
`New York, NY 10018
`Tel: (212) 813 8800
`lcipriano@goodwinlaw.com
`
`Daryl Wiesen (pro hac vice
`application to be filed)
`GOODWIN PROCTER LLP
`100 Northern Ave.
`Boston, MA 02210
`Tel: (617) 570 1000
`dwiesen@goodwinlaw.com
`
`
`Respectfully submitted,
`
`
`
`
`/Jeffrey J. Oelke/
`Jeffrey J. Oelke (Reg. No. 37,409)
`
`Counsel for Novo Nordisk A/S
`
`2
`
`
`
`
`
`Date: September 7, 2022
`
`
`
`
`
`
`
`
`
Accessing this document will incur an additional charge of $.
After purchase, you can access this document again without charge.
Accept $ Charge
Still Working On It
This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.
Give it another minute or two to complete, and then try the refresh button.
A few More Minutes ... Still Working
It can take up to 5 minutes for us to download a document if the court servers are running slowly.
Thank you for your continued patience.
This document could not be displayed.
We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.
Your account does not support viewing this document.
You need a Paid Account to view this document. Click here to change your account type.
Your account does not support viewing this document.
Set your membership
status to view this document.
With a Docket Alarm membership, you'll
get a whole lot more, including:
- Up-to-date information for this case.
- Email alerts whenever there is an update.
- Full text search for other cases.
- Get email alerts whenever a new case matches your search.
One Moment Please
The filing “” is large (MB) and is being downloaded.
Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.
Your document is on its way!
If you do not receive the document in five minutes, contact support at support@docketalarm.com.
Sealed Document
We are unable to display this document, it may be under a court ordered seal.
If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.
Access Government Site
